Physician profile
Thomas T Kason
NPI 1932163037
$3,136.25
in general payments reported to CMS, 2019-2025
24 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $356 · 2021: $248 · 2022: $866 · 2023: $486 · 2024: $389 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,091.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $727.93 | 2022 | |
| Novartis Pharmaceuticals Corporation | $436.61 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $402.35 | 2019-2023 | Xarelto |
| Pfizer INC. | $244.75 | 2019-2025 | |
| Amgen INC. | $223.55 | 2019-2025 | Repatha |
| Medtronic, INC. | $180.69 | 2021-2023 | Corevalve Evolut R |
| W. L. Gore & Associates, INC. | $122.35 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $112.35 | 2019-2025 | Eliquis, Camzyos |
| Chiesi USA, INC. | $105.81 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $100.56 | 2019-2024 | Wainua, Brilinta, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.28 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.80 | 2019-2024 | Lifevest |
| Scpharmaceuticals INC. | $53.27 | 2023-2024 | |
| Amarin Pharma, INC. | $51.30 | 2019-2020 | |
| Inspire Medical Systems, INC. | $39.83 | 2024 | Inspire |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $27.32 | 2025 | Wegovy |
| Siemens Medical Solutions USA, INC. | $26.95 | 2025 | |
| Abbott Laboratories | $23.65 | 2024 | Cardiomems |
| Esperion Therapeutics, INC. | $21.16 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $20.82 | 2023 | Arcalyst |
| Edwards Lifesciences Corporation | $19.23 | 2024 | |
| Sanofi-Aventis U.S. LLC | $19.09 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.81 | 2019 | |
| Medtronic Vascular, INC. | $11.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.